Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...